Skip to Main Content

DOJ’s $678 Million Novartis Settlement for False Claims Act and Anti-Kickback Statute Violations—Changing Big Pharma’s Expectations for Compliance Programs

This Bulletin is brought to you by AHLA’s Fraud and Abuse Practice Group.
  • September 17, 2020
  • Roopa Chakkappan , Hodgson Russ LLP

On July 1, 2020, amidst the chaos of the global COVID-19 pandemic, the Acting United States Attorney for the Southern District of New York, Audrey Strauss, announced that the United States settled a civil fraud lawsuit against Novartis Pharmaceuticals Corporation.

You must be logged in to access this content.